Dermatan sulphate in patients with heparin-induced thrombocytopenia
| Autor: | Giuseppe G. Nenci, F. Gianese, Maria Rita Taliani, Giancarlo Agnelli |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.drug_class Anticoagulant Chondroitin sulfate B Low molecular weight heparin Hematology Heparin medicine.disease Thrombosis Gastroenterology Surgery Internal medicine Heparin-induced thrombocytopenia medicine Platelet Thrombus business medicine.drug |
| Zdroj: | British Journal of Haematology. 104:87-89 |
| ISSN: | 0007-1048 |
| Popis: | Patients with thromboembolic diseases who develop heparin-induced thrombocytopenia (HIT) type II require an alternative anticoagulation strategy. Dermatan sulphate (DS) was administered to five patients with thromboembolic diseases who developed HIT type II and showed an in vitro cross-reactivity with low molecular weight heparins. The platelet count and the extension of thrombosis were monitored during DS administration. In four of the five patients the platelet count rapidly increased after heparin was discontinued and DS started. A low platelet count persisted in the single patient with cross-reactivity to DS, up to 4 d after its discontinuation. None of the patients experienced thrombus extension, haemorrhagic side-effects or other adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text